Publications by authors named "Susan Weil"

Claim this Profile
R
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Thomas J Herzog, Sandro Pignata, Sharad A Ghamande, Maria-Jesús Rubio, Keiichi Fujiwara, Susan C Weil

Gynecol Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.
Robin L Jones, Sant P Chawla, Steven Attia, Patrick Schöffski, Hans Gelderblom, Susan C Weil

Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.
Sandra P D'Angelo, Omid A Hamid, Ahmad Tarhini, Dirk Schadendorf, Bartosz Chmielowski, Susan C Weil

Invest New Drugs· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer.
Axel Grothey, Jonathan R Strosberg, Lindsay A Renfro, Herbert I Hurwitz, John L Marshall, Susan C Weil

Clin Cancer Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.
Wenquan Wang, Elizabeth B Somers, Erin N Ross, J Bradford Kline, Daniel J O'Shannessy, Susan Weil

Cytogenet Genome Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
Marlène C H Hekman, Otto C Boerman, Desirée L Bos, Leon F A G Massuger, Susan Weil

Mol Pharm· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer.
Daniel J O'Shannessy, Katie Bendas, Charles Schweizer, Wenquan Wang, Earl Albone, Susan Weil

Genomics· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
Ignace Vergote, Deborah Armstrong, Giovanni Scambia, Michael Teneriello, Jalid Sehouli, Susan C Weil

J Clin Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
Kenneth H Kim, Danijela Jelovac, Deborah K Armstrong, Benjamin Schwartz, Susan C Weil

Gynecol Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.
Luis A Diaz, Christina M Coughlin, Susan C Weil, Jean Fishel, Mrinal M Gounder

Clin Cancer Res· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Deborah K Armstrong, Allen J White, Susan C Weil, Martin Phillips, Robert L Coleman

Gynecol Oncol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.
Colm Farrell, Charles Schweizer, Jason Wustner, Susan Weil, Masayuki Namiki

Cancer Chemother Pharmacol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
Raffit Hassan, Steven J Cohen, Martin Phillips, Ira Pastan, Elad Sharon, Susan Weil

Clin Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
Jason A Konner, Katherine M Bell-McGuinn, Paul Sabbatini, Martee L Hensley, William P Tew, Susan C Weil

Clin Cancer Res· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
Raffit Hassan, Charles Schweizer, Kun F Lu, Barbara Schuler, Alan T Remaley, Susan C Weil

Lung Cancer· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk.
Xiaowei Chen, Joellen Weaver, Betsy A Bove, Lisa A Vanderveer, Susan C Weil

Hum Mol Genet· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A training course for oncology nurses in familial cancer risk assessment: evaluation of knowledge and practice.
Agnes Masny, Mary Daly, Eric Ross, Andrew Balshem, Doris Gillespie, Susan Weil

J Cancer Educ· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis